Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086216
Status:
COMPLETED
Last Update Posted:
2007-12-21
First Post:
2004-06-28
Brief Title:
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
Sponsor:
Callisto Pharmaceuticals
Organization:
Callisto Pharmaceuticals
Organization Data
Organization:
Callisto Pharmaceuticals
Class:
INDUSTRY
Study ID:
CP-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Callisto Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Gary Jacob
Old Organization:
Callisto Pharmaceuticals